Highlander Capital Management LLC Has $1.36 Million Position in Bristol-Myers Squibb Co (BMY)

Highlander Capital Management LLC increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 304.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,924 shares of the biopharmaceutical company’s stock after buying an additional 16,500 shares during the quarter. Highlander Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,360,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $101,000. Institutional & Family Asset Management LLC bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $106,000. Delphi Private Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $108,000. Centerpoint Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 373.1% in the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 1,399 shares in the last quarter. Finally, NuWave Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $119,000. Institutional investors own 71.37% of the company’s stock.

Shares of Bristol-Myers Squibb traded down $0.03, hitting $53.43, during trading hours on Thursday, MarketBeat reports. 26,783 shares of the company’s stock were exchanged, compared to its average volume of 8,464,142. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.52 and a quick ratio of 1.39. The company has a market cap of $86.83 billion, a price-to-earnings ratio of 17.82, a PEG ratio of 1.39 and a beta of 0.95. Bristol-Myers Squibb Co has a fifty-two week low of $49.96 and a fifty-two week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The firm had revenue of $5.19 billion during the quarter, compared to analysts’ expectations of $5.25 billion. During the same period in the previous year, the business earned $0.84 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. analysts anticipate that Bristol-Myers Squibb Co will post 3.43 earnings per share for the current fiscal year.

In other news, Director Dinesh C. Paliwal purchased 4,770 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The stock was purchased at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the transaction, the director now owns 8,027 shares of the company’s stock, valued at $420,614.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.12% of the stock is currently owned by insiders.

BMY has been the subject of several recent research reports. Citigroup set a $78.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, February 16th. Argus reiterated a “buy” rating and issued a $66.43 target price (down previously from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, March 21st. TheStreet lowered Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. Morgan Stanley lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $54.08 to $58.00 in a research note on Tuesday, April 17th. Finally, Barclays cut their target price on Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Friday, April 27th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $62.84.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit